| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.11B | -11.5% |
| Gross profit | ¥0.04B | — |
| Operating income | ¥-0.02B | — |
| Net income | ¥-0.02B | — |
| Gross margin | 37.9% | Net margin -15.7% |
| Revenue Q/Q | -64.2% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.07B | 62.1% |
| R&D | ¥0.01B | 11.0% |
| SG&A | ¥0.05B | 46.5% |
| Tax & other | ¥-0.00B | -0.2% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
百纳千成 ・ 吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份 ・ 海峡创新 ・ ST长方 ・ 同有科技 ・ 聚飞光电
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies